Climb Bio, Inc. (CLYM): Insider Trades and Fund Holdings
In the past 12 months, Climb Bio, Inc. insiders reported 0 open-market purchases worth $0 and 1 sale worth $1.37M; 1 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.
- Sep 15, 2026Insider saleDirector Stephen Basil Thomas sold $1.4 million under a 10b5-1 plan
- Sep 15, 2026Planned saleSTEPHEN THOMAS (director) filed notice to sell about $1.5 million around Sep 15, 2026
- Jun 30, 2026FundRenaissance Technologies cut 11% in Q2 2026 (13F filed Aug 13, 2026)
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 17, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 17 | Stephen Basil ThomasDirector | ▼ SELL10b5-1 | $1.37M |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Stephen Basil Thomas | Director | 0 | $0 | 1 | $1.37M |
Tracked funds that report CLYM
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 192,700 | $2.51M | ▼ −11.3% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →